Lifecore Biomedical (NASDAQ:LFCR) Given “Equal Weight” Rating at Stephens

Lifecore Biomedical (NASDAQ:LFCR)‘s stock had its “equal weight” rating reiterated by research analysts at Stephens in a research note issued on Friday,Benzinga reports. They presently have a $6.00 price target on the stock. Stephens’ price target points to a potential downside of 9.91% from the stock’s current price.

Separately, Craig Hallum raised their price objective on shares of Lifecore Biomedical from $8.00 to $10.00 and gave the company a “buy” rating in a report on Friday, November 22nd.

Lifecore Biomedical Trading Down 10.4 %

Shares of Lifecore Biomedical stock opened at $6.66 on Friday. The firm’s 50 day moving average is $6.98 and its 200 day moving average is $5.77. The firm has a market capitalization of $245.27 million, a PE ratio of 83.25 and a beta of 0.98. Lifecore Biomedical has a 1 year low of $3.68 and a 1 year high of $8.90. The company has a current ratio of 1.83, a quick ratio of 0.80 and a debt-to-equity ratio of 12.90.

Lifecore Biomedical (NASDAQ:LFCR) last issued its earnings results on Thursday, January 2nd. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.02. Lifecore Biomedical had a negative return on equity of 382.65% and a net margin of 5.09%. Equities research analysts forecast that Lifecore Biomedical will post -0.99 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lifecore Biomedical

Institutional investors have recently modified their holdings of the company. DCF Advisers LLC boosted its holdings in shares of Lifecore Biomedical by 2.1% during the 2nd quarter. DCF Advisers LLC now owns 290,684 shares of the company’s stock worth $1,491,000 after buying an additional 6,000 shares in the last quarter. Renaissance Technologies LLC bought a new stake in Lifecore Biomedical in the second quarter valued at $56,000. Creative Planning acquired a new position in shares of Lifecore Biomedical during the third quarter valued at about $69,000. Legion Partners Asset Management LLC grew its stake in shares of Lifecore Biomedical by 0.6% in the 2nd quarter. Legion Partners Asset Management LLC now owns 2,968,409 shares of the company’s stock valued at $15,228,000 after buying an additional 18,182 shares during the period. Finally, Jane Street Group LLC increased its position in Lifecore Biomedical by 101.7% in the 3rd quarter. Jane Street Group LLC now owns 36,246 shares of the company’s stock valued at $179,000 after buying an additional 18,277 shares in the last quarter. 83.36% of the stock is owned by institutional investors.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.